Hartsell & Associates National
Legal Nurse Consultants 

National Alliance of Certified Legal Nurse Consultants
Nurse Alliance of Tennessee
American Nurses Association

Assisting Attorneys To Victory By Providing Over 33 Years Healthcare Expertise

V.I.P. Member of the Manchester Who's Who Among Executive and Professional Women

 

Newsletter

November  2006

Volume 1, No 14


 
Gene Therapy in Metastatic Cancer

November 21, 2006

"We have demonstrated that gene-modified T cells can recognize and kill melanoma cells overexpressing a specific antigen, leading to a clinical response in some patients," said Dr. Rosenberg. "With this trial, we hope to extend this type of immunotherapy to patients with more common cancers."

Patients in this trial will be separated into two treatment groups. Patients with melanoma and renal cell cancer (diseases that respond to IL-2 therapy) will form one group, and those with other types of metastatic cancer will form the other group

Principal Investigator
Dr. Steven A. Rosenberg, NCI CCR

Source:  National Cancer Institute

For the full article:

 http://www.cancer.gov/ncicancerbulletin/
NCI_Cancer_Bulletin_112106/pag
e6
 

Patient-Controlled Oral Analgesia:  A Low-Tech
Solution in a High-Tech World
 
Posted 11/16/2006

The primary concern of surgical patients is the expected experience of pain. Presently, the standard for acute postoperative pain management is intravenous patient-controlled analgesia (PCA). Many authors have reported that patients prefer intravenous PCA to nurse-administered analgesia because it affords them greater control and optimizes their pain relief. However, when the patient strengthens and is able to resume enteral sustenance, intravenous PCA is routinely discontinued and replaced with nurse-administered oral analgesia.

This eliminates much of the patients' control over managing their pain and results in patients waiting, in pain, for a nurse to bring their pain tablets. When PCA is administered in the hospital setting, it is most often administered by intravenous, subcutaneous, or epidural routes. This article describes the implementation of a successful inpatient program that offers patient-controlled oral analgesia (PCOA).

Patient-centered care is "an approach that consciously adopts the patient's perspective...about what matters." Patient-centered care is the practice philosophy of the University Health Network, a large tri-site teaching hospital in downtown Toronto, Ontario, Canada, affiliated with the University of Toronto. This philosophy underpins the concept of PCOA as it has been successfully operationalized in a unique PCOA program at the Toronto Western Hospital, one of the three sites comprising the University Health Network.

Source:http://www.medscape.com/viewarticle/
546940

Undertreatment of Postoperative Pain Have Serious Consequences

Despite medical, technologic, and pharmaceutical advancement in the past decade, inadequate management of postoperative pain remains common (Coley, Williams, DaPos, Chen, & Smith, 2002; Watt-Watson, Garfinkel, Gallop, Stevens, & Streiner, 2000; Watt-Watson, Stevens, Costello, Katz, & Reid, 2000). Approximately 80% of patients experience acute pain after surgery, and of these, 47% report severe or extreme pain (Apfelbaum, Chen, Mehta, & Gan, 2003).

Adverse effects of unrelieved pain include deep vein thrombosis, pulmonary embolism, coronary ischemia, myocardial infarction, pneumonia, poor wound healing, insomnia, and demoralization (Carr & Goudas, 1999). In addition, undertreated pain can result in longer intensive care unit and hospital stays (Bertollni et al., 2002), interference with activities of daily living at discharge (Moore, 1994), and a high incidence of chronic pain development (Katz, Jackson, Kavanagh, & Sandler, 1996).

         ________________________________________________________________________
 
If Hartsell Medical-Legal Consulting Services Can Assist You Or If You Would Like To
See A Particular Subject In The Newsletter, Please Contact:
Telephone:
423-587-2545
 
Electronic Mail:

medlegalanalysis@charter.net   or
hartsell@hartsellmedconsulting.com

Fax:
423-587-2547
 

Back to Newsletter Index Here